AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PHIO

Bitterman Robert J purchased $20K of PHIO

Bitterman Robert J (Chairman, Pres. & CEO) purchased 25,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.82 on 2026-11-09.

Original reporting
SEC EDGAR · Bitterman Robert J
Published Nov 10, 2026, 4:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHIO
Neutral
high confidence
Mentioned
$PHIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHIONeutralLow
01

Why it matters

The purchase is modest and unlikely to affect PHIO's stock price significantly.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could make the purchase more meaningful.

Relevance 4/10Novelty 3/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$PHIONeutralHigh confidence
Context

Insider Chairman Robert J. Bitterman bought 25,000 PHIO shares at $0.82 each, a $20.5K purchase.

Expected impact

modest upward pressure as market views insider buying positively

Evidence & confidence

Purchase size is tiny relative to market cap; impact limited to short‑term sentiment.

Market effects

Sector

Minimal effect on biotech sector; typical insider activity.

Regional

No regional impact.

Global

Not relevant globally.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing, not a bullish signal.

Key entities

  • Company
    Phio Pharmaceuticals Corp.

    Biopharma company developing therapies.

  • Individual
    Robert J. Bitterman

    Chairman, President & CEO of PHIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHIO insider trading history →

Related articles

$PHIOMedAI 8/10

Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

Phio Pharmaceuticals (PHIO) presented Phase 1b trial data for its cancer treatment PH-762 at the ASDS Annual Meeting. The study suggested PH-762 is well-tolerated and may offer a tissue-sparing neoadjuvant therapy for cutaneous carcinomas. A Phase 2b study is planned for 2027. According to the company, PH-762 could improve patient outcomes by shrinking tumors before surgery.

timminspress.com
$PHIOMedAI 8/10

Phio Pharmaceuticals 3Q 2026: EPS ($0.36) — 10-Q Summary

Phio Pharmaceuticals reported a wider net loss of $4.16M in 3Q 2026, up 73.9% YoY, due to increased R&D and regulatory costs. EPS was ($0.36). The company advanced PH-762 toward a Phase 2b study, with a 65% response rate in Phase 1b trials. Manufacturing of PH-762 drug substance began in 3Q 2026.

tradingview.com
$PHIOMed

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatmen

SEC EDGAR 8-K